Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
BridgeBio Pharma, Inc. (BBIO)
USD83.08
-2.81 (-3.27%)
US NASDAQ Healthcare Biotechnology
Address
421 Kipling Street 94301
Palo Alto, CA, US
Palo Alto, CA, US
CEO
Neil Kumar
Website
bridgebio.com
IPO
2019-06-27
CIK 1743881 ISIN US10806X1028
Description
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases. Notable candidates within its development pipeline include: AG10 and BBP-265: A small molecule designed to stabilize transthyretin (TTR), currently in a pivotal Phase 3 clinical trial targeting transthyretin amyloidosis-cardiomyopathy (ATTR-CM). BBP-831: A selective small molecule inhibitor of FGFR1-3, which is undergoing Phase 2 clinical evaluation for treating achondroplasia in pediatric patients. BBP-631: An AAV5 gene transfer product candidate, also in Phase 2 clinical trials, aimed at congenital adrenal hyperplasia (CAH) caused by 21-hydroxylase deficiency (21OHD). Furthermore, BridgeBio is developing: Encaleret: A small molecule antagonist of the calcium sensing receptor (CaSR), presently in a Phase 2 proof-of-concept study for Autosomal Dominant Hypocalcemia Type 1 (ADH1). BBP-711: Intended for the management of hyperoxaluria and individuals prone to recurring kidney stones. Beyond these specific programs, the company is actively engaged in developing therapies for a broader range of Mendelian disorders, oncological diseases, and gene therapy applications. BridgeBio Pharma, Inc. maintains strategic licensing and collaboration agreements with institutions such as Leland Stanford Junior University, The Regents of the University of California, and Leidos Biomedical Research, Inc. Established in 2015, the company's corporate headquarters are situated in Palo Alto, California.
News Sentiment (7d)
5 articles
- BridgeBio: "Strong Buy" Attruby Differentiation And Several NDA Submissions In Play Seeking Alpha
- How a Rival's Clinical Setback Sent BBIO Stock to a 52-Week High Zacks Investment Research
- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) GlobeNewsWire
- The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions MarketBeat
Market Cap & Enterprise Value
Merger & Acquisition History
| Target company | Ticker | Date | Filing |
|---|---|---|---|
| Eidos | EIDX | 2020-11-06 | View |
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD83.08
-2.81 (-3.27%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.95
Float Shares
161.20M
Free Float %
83.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.02% | -5.69% | -13.29% | -14.96% | -2.33% | -15.44% | +81.28% | +377.34% | +30.72% | +134.77% | +134.77% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (26 ratings, all time)
Buy
Price Targets & DCF
Current price
83.08
Low
83.00
-0.1%
Consensus
105.15
+26.6%
Median
100.00
+20.4%
High
157.00
+89.0%
Ratings Trend (MoM)
96% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 6 | 0 |
| Buy | 16 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 2 |
101.00
+21.6%
|
| Last Quarter | 9 |
96.33
+15.9%
|
| Last Year | 24 |
92.08
+10.8%
|
| All Time | 38 |
74.71
-10.1%
|
Quality scores
Altman Z-Score
-2.71
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Composite Rating
C
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+126.3% ★ Q1'26: +66.8% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%-31.6% Q1'26: +4.5% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-155.1% Q1'26: -101.5% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-135.8% Q1'26: -54.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-1,063.9% Q1'26: -242.4% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+6.0% Q1'26: +2.4% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-4.06× Q1'26: -8.08× (vs Q1'25)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 12 EPS Ana. |
Dec 2027 16 Rev. Ana. 11 EPS Ana. |
Dec 2028 17 Rev. Ana. 16 EPS Ana. |
Dec 2029 14 Rev. Ana. 14 EPS Ana. |
Dec 2030 8 Rev. Ana. 14 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
40.56M
est: 26.81M (+51.3%)
|
8.25M
est: 22.52M (-63.4%)
|
69.72M
est: 78.26M (-10.9%)
|
77.65M
est: 82.75M (-6.2%)
|
9.30M
est: 219.12M (-95.8%)
|
221.90M
est: 219.08M (+1.3%)
|
502.08M
est: 496.34M (+1.2%)
|
939.23M
798.74M – 1.06B
+89.2% YoY
|
1.60B
1.11B – 1.86B
+70.4% YoY
|
2.41B
2.41B – 2.42B
+50.8% YoY
|
3.35B
2.72B – 3.90B
+38.7% YoY
|
4.24B
3.44B – 4.94B
+26.7% YoY
|
| EBITDA |
-278.96M
est: -26.81M (-940.6%)
|
-467.38M
est: -353.32M (-32.3%)
|
-533.83M
est: -404.92M (-31.8%)
|
-397.44M
est: -509.67M (+22.0%)
|
-565.47M
est: -219.12M (-158.1%)
|
-436.83M
est: -219.08M (-99.4%)
|
-672.88M
est: -496.34M (-35.6%)
|
-939.23M
-1.06B – -798.74M
-89.2% YoY
|
-1.60B
-1.86B – -1.11B
-70.4% YoY
|
-2.41B
-2.42B – -2.41B
-50.8% YoY
|
-3.35B
-3.90B – -2.72B
-38.7% YoY
|
-4.24B
-4.94B – -3.44B
-26.7% YoY
|
| EBIT |
-279.82M
est: -26.81M (-943.8%)
|
-468.83M
est: -383.77M (-22.2%)
|
-539.68M
est: -459.83M (-17.4%)
|
-404.21M
est: -560.35M (+27.9%)
|
-571.96M
est: -219.12M (-161.0%)
|
-442.90M
est: -219.08M (-102.2%)
|
-681.88M
est: -496.34M (-37.4%)
|
-939.23M
-1.06B – -798.74M
-89.2% YoY
|
-1.60B
-1.86B – -1.11B
-70.4% YoY
|
-2.41B
-2.42B – -2.41B
-50.8% YoY
|
-3.35B
-3.90B – -2.72B
-38.7% YoY
|
-4.24B
-4.94B – -3.44B
-26.7% YoY
|
| Net Income |
-260.44M
est: -514.37M (+49.4%)
|
-448.72M
est: -362.63M (-23.7%)
|
-562.54M
est: -450.77M (-24.8%)
|
-481.18M
est: -570.76M (+15.7%)
|
-643.20M
est: -453.82M (-41.7%)
|
-535.76M
est: -492.91M (-8.7%)
|
-729.31M
est: -674.79M (-8.1%)
|
-383.99M
-684.95M – -219.94M
+43.1% YoY
|
117.11M
-357.83M – 439.35M
+130.5% YoY
|
759.82M
146.76M – 1.21B
+548.8% YoY
|
1.36B
1.03B – 1.65B
+78.9% YoY
|
1.86B
1.41B – 2.26B
+36.9% YoY
|
| SGA |
94.35M
est: 213.12M (-55.7%)
|
145.68M
est: 179.05M (-18.6%)
|
192.21M
est: 622.16M (-69.1%)
|
143.19M
est: 657.87M (-78.2%)
|
150.59M
est: 1.02B (-85.2%)
|
288.93M
est: 1.02B (-71.6%)
|
555.14M
est: 2.30B (-75.9%)
|
4.36B
3.71B – 4.90B
+89.2% YoY
|
7.42B
5.17B – 8.65B
+70.4% YoY
|
11.19B
11.18B – 11.21B
+50.8% YoY
|
15.52B
12.60B – 18.09B
+38.7% YoY
|
19.66B
15.96B – 22.92B
+26.7% YoY
|
| EPS |
-2.48
est: -2.76 (+10.3%)
|
-4.10
est: -3.52 (-16.4%)
|
-3.90
est: -3.70 (-5.4%)
|
-3.35
est: -3.13 (-7.0%)
|
-3.95
est: -2.58 (-53.2%)
|
-2.88
est: -2.51 (-14.6%)
|
-3.79
est: -3.44 (-10.1%)
|
-2.18
-3.47 – -1.12
+36.7% YoY
|
0.54
-1.81 – 2.23
+124.8% YoY
|
3.57
0.74 – 6.14
+560.8% YoY
|
6.89
5.21 – 8.38
+93.3% YoY
|
9.44
7.13 – 11.47
+36.9% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-29 | Truist Securities | Buy | Buy | Maintain |
| 2026-04-28 | Mizuho | Outperform | Outperform | Maintain |
| 2026-04-27 | HC Wainwright & Co. | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-15 | C | 2/5 | 1/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-378.70M
OE per share TTM
-1.96
Owner's Yield
-2.88%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
17.2%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
112
Total invested
254.11M
Insider transactions (90d)
1
Beneficial owners (>5%)
23
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Eidos Therapeutics, Inc. | 44.65M | 36.40% | — | 44.65M | — | — | CO | — | 2020-10-15 | ↗ |
| 2 | David C. Ott | 25.12M | 15.70% | — | 25.12M | — | 25.12M | IN | — | 2023-07-20 | ↗ |
| 3 | O. Andreas Halvorsen | 25.12M | 15.70% | — | 25.12M | — | 25.12M | IN | — | 2023-07-20 | ↗ |
| 4 | Rose S. Shabet | 25.12M | 15.70% | — | 25.12M | — | 25.12M | IN | — | 2023-07-20 | ↗ |
| 5 | Viking Global Investors LP | 25.12M | 15.70% | — | 25.12M | — | 25.12M | PN | — | 2023-07-20 | ↗ |
| 6 | Viking Global Opportunities GP LLC | 24.24M | 15.10% | — | 24.24M | — | 24.24M | OO | — | 2023-07-20 | ↗ |
| 7 | Viking Global Opportunities Illiquid Investments Sub-Master LP | 24.24M | 15.10% | — | 24.24M | — | 24.24M | PN | — | 2023-07-20 | ↗ |
| 8 | Viking Global Opportunities Parent GP LLC | 24.24M | 15.10% | — | 24.24M | — | 24.24M | OO | — | 2023-07-20 | ↗ |
| 9 | Viking Global Opportunities Portfolio GP LLC | 24.24M | 15.10% | — | 24.24M | — | 24.24M | OO | — | 2023-07-20 | ↗ |
| 10 | (1) BlackRock, Inc. | 12.88M | 6.80% | — | — | 12.88M | — | HC | Delaware | 2024-10-22 | ↗ |
| 11 | The Vanguard Group - 23-1945930 | 9.33M | 6.34% | — | 156.6K | 9.10M | 236.3K | IA | Pennsylvania | 2022-02-09 | ↗ |
| 12 | STATE STREET CORPORATION | 8.84M | 5.92% | — | 8.50M | — | — | HC | — | 2023-02-08 | ↗ |
| 13 | NEIL KUMAR | 8.33M | 6.74% | 5.52M | 2.81M | 5.52M | 2.81M | IN | U.S. | 2021-02-16 | ↗ |
| 14 | Management (U.S.), LLC | 6.73M | 5.50% | — | 6.73M | — | — | HC | under the laws of the State of Delaware | 2020-02-14 | ↗ |
| 15 | Joseph Edelman | 6.71M | 5.50% | — | 6.71M | — | 6.71M | IN | Delaware | 2021-02-16 | ↗ |
| 16 | Perceptive Advisors LLC | 6.71M | 5.50% | — | 6.71M | — | 6.71M | IA | Delaware | 2021-02-16 | ↗ |
| 17 | Perceptive Life Sciences Master Fund, Ltd. | 6.71M | 5.50% | — | 6.71M | — | 6.71M | CO | Delaware | 2021-02-16 | ↗ |
| 18 | 10 | 6.59M | 5.50% | — | 6.59M | — | 6.59M | IN | United States of America | 2019-07-11 | ↗ |
| 19 | 5.5% | 6.59M | 5.50% | — | 6.59M | — | 6.59M | CO | United States of America | 2019-07-11 | ↗ |
| 20 | Viking Global Equities Master Ltd. | 631.2K | 0.40% | — | 631.2K | — | 631.2K | CO | — | 2023-07-20 | ↗ |
| 21 | Viking Global Performance LLC | 631.2K | 0.40% | — | 631.2K | — | 631.2K | OO | — | 2023-07-20 | ↗ |
| 22 | Viking Long Fund GP LLC | 251.2K | 0.20% | — | 251.2K | — | 251.2K | OO | — | 2023-07-20 | ↗ |
| 23 | Viking Long Fund Master Ltd. | 251.2K | 0.20% | — | 251.2K | — | 251.2K | CO | — | 2023-07-20 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
112
-362 vs prev Q
New positions
25
Closed positions
355
Increased
59
Reduced
29
Put/Call ratio
0.45
Calls held
133.6K
Puts held
60.0K
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 1.73M +1.7M (+100.0%) | 131.97B +132.0B (+100.0%) | 0.91% +0.906 pp | 0.20% +0.199 pp | USD76.49 +0.0% | 1 qtrs NEW |
| 2 | VANGUARD GROUP INC | 16.86M +30.6K (+0.2%) | 1.29B +415.6M (+47.5%) | 8.85% +0.016 pp | 0.02% +0.006 pp | USD37.02 +106.6% | 27 qtrs — |
| 3 | BLACKROCK, INC. | 14.55M +138.3K (+1.0%) | 1.11B +364.4M (+48.7%) | 7.64% +0.073 pp | 0.02% +0.006 pp | USD27.43 +178.9% | 6 qtrs — |
| 4 | VIKING GLOBAL INVESTORS LP | 14.39M -1.6M (-9.9%) | 1.10B +271.1M (+32.7%) | 7.56% -0.831 pp | 2.92% +0.767 pp | USD27.37 +179.5% | 27 qtrs — |
| 5 | KOHLBERG KRAVIS ROBERTS & CO. L.P. | 13.26M +— (+0.0%) | 1.01B +325.6M (+47.3%) | 6.96% +0.000 pp | 16.22% +4.675 pp | USD27.37 +179.5% | 27 qtrs — |
| 6 | JANUS HENDERSON GROUP PLC | 11.00M +2.3M (+25.8%) | 841.35M +387.4M (+85.3%) | 5.77% +1.186 pp | 0.38% +0.170 pp | USD41.80 +83.0% | 27 qtrs — |
| 7 | FARALLON CAPITAL MANAGEMENT LLC | 9.00M +806.5K (+9.8%) | 688.29M +262.8M (+61.8%) | 4.72% +0.423 pp | 3.25% +1.506 pp | USD37.26 +105.3% | 6 qtrs — |
| 8 | AISLING CAPITAL MANAGEMENT LP | 5.09M -1.0M (-16.4%) | 389.30M +73.0M (+23.1%) | 2.67% -0.525 pp | 81.29% +11.994 pp | USD39.18 +95.2% | 27 qtrs — |
| 9 | STATE STREET CORP | 4.96M -643.5K (-11.5%) | 379.61M +88.4M (+30.4%) | 2.60% -0.338 pp | 0.01% +0.003 pp | USD19.38 +294.7% | 26 qtrs — |
| 10 | INVESCO LTD. | 4.83M +902.6K (+23.0%) | 369.55M +165.5M (+81.1%) | 2.54% +0.474 pp | 0.06% +0.025 pp | USD45.39 +68.5% | 25 qtrs — |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 4.41M +502.6K (+12.9%) | 344.69M +141.6M (+69.7%) | 2.32% +0.264 pp | 0.02% +0.008 pp | USD39.28 +94.7% | 26 qtrs — |
| 12 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.83M +2.3M (+144.2%) | 292.86M +211.4M (+259.7%) | 2.01% +1.187 pp | 0.03% +0.023 pp | USD62.31 +22.8% | 24 qtrs — |
| 13 | FRAZIER LIFE SCIENCES MANAGEMENT, L.P. | 3.55M -299.9K (-7.8%) | 271.20M +71.5M (+35.8%) | 1.86% -0.157 pp | 7.28% +1.299 pp | USD22.30 +243.0% | 12 qtrs — |
| 14 | JANE STREET GROUP, LLC | 3.42M +68.4K (+2.0%) | 261.37M +87.4M (+50.3%) | 1.79% +0.036 pp | 0.04% +0.013 pp | USD30.61 +149.9% | 6 qtrs — |
| 15 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 2.67M -308.1K (-10.3%) | 204.25M +49.6M (+32.0%) | 1.40% -0.162 pp | 0.02% +0.006 pp | USD25.07 +205.1% | 24 qtrs — |
| 16 | FMR LLC | 2.39M +689.6K (+40.5%) | 182.84M +94.5M (+107.0%) | 1.25% +0.362 pp | 0.01% +0.005 pp | USD41.96 +82.3% | 27 qtrs — |
| 17 | WELLINGTON MANAGEMENT GROUP LLP | 2.35M +1.3M (+130.4%) | 179.65M +126.7M (+239.4%) | 1.23% +0.698 pp | 0.03% +0.022 pp | USD65.24 +17.2% | 10 qtrs — |
| 18 | D. E. SHAW & CO., INC. | 2.21M -38.7K (-1.7%) | 169.35M +52.3M (+44.7%) | 1.16% -0.020 pp | 0.09% +0.027 pp | USD43.53 +75.7% | 20 qtrs — |
| 19 | FRANKLIN RESOURCES INC | 2.16M +720.9K (+49.9%) | 165.60M +90.6M (+120.8%) | 1.14% +0.378 pp | 0.04% +0.022 pp | USD55.42 +38.0% | 8 qtrs — |
| 20 | ALLIANCEBERNSTEIN L.P. | 2.05M -278.0K (-11.9%) | 156.86M +35.9M (+29.7%) | 1.08% -0.146 pp | 0.05% +0.011 pp | USD26.41 +189.6% | 25 qtrs — |
| 21 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 1.98M +60.5K (+3.2%) | 151.01M +51.6M (+51.8%) | 1.04% +0.032 pp | 0.12% +0.042 pp | USD28.66 +166.9% | 26 qtrs — |
| 22 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.96M +39.2K (+2.0%) | 150.26M +50.3M (+50.3%) | 1.03% +0.021 pp | 0.02% +0.007 pp | USD40.20 +90.3% | 26 qtrs — |
| 23 | TWO SIGMA INVESTMENTS, LP | 1.95M -381.9K (-16.4%) | 148.93M +28.0M (+23.1%) | 1.02% -0.201 pp | 0.21% +0.030 pp | USD38.41 +99.1% | 22 qtrs — |
| 24 | CAPITAL RESEARCH GLOBAL INVESTORS | 1.93M +1.6K (+0.1%) | 147.99M +47.6M (+47.4%) | 1.02% +0.001 pp | 0.03% +0.009 pp | USD29.40 +160.2% | 10 qtrs — |
| 25 | UBS GROUP AG | 1.88M -710.8K (-27.5%) | 143.47M +9.1M (+6.8%) | 0.98% -0.373 pp | 0.02% +0.002 pp | USD34.86 +119.4% | 27 qtrs — |
| 26 | SC US (TTGP), LTD. | 1.86M +— (+0.0%) | 142.30M +45.7M (+47.3%) | 0.98% +0.000 pp | 1.02% +0.420 pp | USD27.37 +179.5% | 27 qtrs — |
| 27 | GOLDMAN SACHS GROUP INC | 1.78M -426.3K (-19.3%) | 136.37M +21.6M (+18.8%) | 0.94% -0.224 pp | 0.02% +0.003 pp | USD32.98 +131.9% | 27 qtrs — |
| 28 | DRIEHAUS CAPITAL MANAGEMENT LLC | 1.68M +18.9K (+1.1%) | 128.58M +42.2M (+48.9%) | 0.88% +0.010 pp | 0.87% +0.255 pp | USD36.00 +112.5% | 4 qtrs — |
| 29 | BNP PARIBAS ARBITRAGE, SNC | 1.59M +953.4K (+149.1%) | 121.82M +88.6M (+266.9%) | 0.84% +0.500 pp | 0.06% +0.038 pp | USD62.31 +22.8% | 26 qtrs — |
| 30 | NORGES BANK | 1.53M +1.5M (+100.0%) | 116.80M +116.8M (+100.0%) | 0.80% +0.802 pp | 0.01% +0.013 pp | USD76.49 +0.0% | 1 qtrs NEW |
| 31 | LAURION CAPITAL MANAGEMENT LP | 1.40M -351.4K (-20.0%) | 107.25M +16.2M (+17.8%) | 0.74% -0.184 pp | 3.99% +2.428 pp | USD15.49 +393.8% | 16 qtrs — |
| 32 | TWO SIGMA ADVISERS, LP | 1.40M -261.7K (-15.7%) | 107.17M +20.8M (+24.1%) | 0.74% -0.137 pp | 0.21% +0.036 pp | USD41.78 +83.1% | 21 qtrs — |
| 33 | MORGAN STANLEY | 1.40M +344.9K (+32.7%) | 107.07M +52.3M (+95.4%) | 0.73% +0.181 pp | 0.01% +0.003 pp | USD39.24 +94.9% | 27 qtrs — |
| 34 | NORTHERN TRUST CORP | 1.35M -55.7K (-4.0%) | 103.01M +30.2M (+41.4%) | 0.71% -0.029 pp | 0.01% +0.004 pp | USD32.37 +136.3% | 26 qtrs — |
| 35 | PRINCIPAL FINANCIAL GROUP INC | 1.31M +46.9K (+3.7%) | 100.53M +34.7M (+52.7%) | 0.69% +0.025 pp | 0.05% +0.018 pp | USD35.47 +115.6% | 24 qtrs — |
| 36 | POLAR CAPITAL HOLDINGS PLC | 1.30M +318.3K (+32.4%) | 99.39M +48.4M (+95.0%) | 0.68% +0.167 pp | 0.38% +0.139 pp | USD57.95 +32.0% | 2 qtrs — |
| 37 | PICTET ASSET MANAGEMENT HOLDING SA | 1.27M +136.9K (+12.1%) | 96.96M +38.1M (+64.7%) | 0.67% +0.072 pp | 0.09% +0.037 pp | USD32.97 +132.0% | 10 qtrs — |
| 38 | ENSIGN PEAK ADVISORS, INC | 1.26M -88.1K (-6.5%) | 96.64M +26.4M (+37.7%) | 0.66% -0.046 pp | 0.17% +0.056 pp | USD28.54 +168.0% | 25 qtrs — |
| 39 | HOOD RIVER CAPITAL MANAGEMENT LLC | 1.26M +11.6K (+0.9%) | 96.01M +31.4M (+48.6%) | 0.66% +0.006 pp | 1.05% +0.290 pp | USD52.17 +46.6% | 2 qtrs — |
| 40 | CORMORANT ASSET MANAGEMENT, LP | 1.20M -200.0K (-14.3%) | 91.79M +19.1M (+26.2%) | 0.63% -0.105 pp | 4.24% -0.773 pp | USD23.38 +227.2% | 27 qtrs — |
| 41 | AMERICAN CENTURY COMPANIES INC | 1.11M +30.2K (+2.8%) | 84.66M +28.7M (+51.4%) | 0.58% +0.016 pp | 0.04% +0.014 pp | USD31.63 +141.8% | 23 qtrs — |
| 42 | BANK OF AMERICA CORP /DE/ | 1.08M -302.8K (-21.9%) | 82.46M +10.7M (+15.0%) | 0.57% -0.159 pp | 0.01% +0.001 pp | USD36.12 +111.8% | 26 qtrs — |
| 43 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 994.2K +987.3K (+14,211.5%) | 77.78M +77.4M (+20,836.1%) | 0.52% +0.518 pp | 0.13% +0.125 pp | USD76.20 +0.4% | 17 qtrs — |
| 44 | JPMORGAN CHASE & CO | 859.0K +564.9K (+192.1%) | 65.70M +50.4M (+330.1%) | 0.45% +0.297 pp | 0.00% +0.003 pp | USD62.86 +21.7% | 27 qtrs — |
| 45 | AMERIPRISE FINANCIAL INC | 841.5K +40.9K (+5.1%) | 64.37M +22.8M (+54.8%) | 0.44% +0.021 pp | 0.01% +0.005 pp | USD32.88 +132.6% | 27 qtrs — |
| 46 | FRONTIER CAPITAL MANAGEMENT CO LLC | 826.1K +166.5K (+25.2%) | 63.19M +28.9M (+84.4%) | 0.43% +0.087 pp | 0.67% +0.363 pp | USD40.80 +87.5% | 8 qtrs — |
| 47 | SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC | 813.8K +7.1K (+0.9%) | 62.25M +20.3M (+48.6%) | 0.43% +0.004 pp | 1.29% +0.425 pp | USD35.98 +112.6% | 4 qtrs — |
| 48 | DEEP TRACK CAPITAL, LP | 810.1K -389.9K (-32.5%) | 61.97M -360.2K (-0.6%) | 0.43% -0.205 pp | 1.10% -0.635 pp | USD37.35 +104.8% | 5 qtrs — |
| 49 | LORD, ABBETT & CO. LLC | 781.3K -95.5K (-10.9%) | 59.77M +14.2M (+31.2%) | 0.41% -0.050 pp | 0.18% +0.048 pp | USD37.92 +101.7% | 4 qtrs — |
| 50 | PANAGORA ASSET MANAGEMENT INC | 738.8K +9.3K (+1.3%) | 56.51M +18.6M (+49.1%) | 0.39% +0.005 pp | 0.20% +0.048 pp | USD30.37 +151.9% | 11 qtrs — |
| 51 | SOFINNOVA INVESTMENTS, INC. | 720.4K -111.4K (-13.4%) | 55.11M +11.9M (+27.5%) | 0.38% -0.059 pp | 2.38% +0.014 pp | USD36.81 +107.8% | 4 qtrs — |
| 52 | CITIGROUP INC | 700.3K -227.7K (-24.5%) | 53.56M +5.4M (+11.1%) | 0.37% -0.120 pp | 0.02% +0.002 pp | USD22.46 +240.6% | 26 qtrs — |
| 53 | CITADEL ADVISORS LLC | 698.2K +698.2K (+100.0%) | 53.40M +53.4M (+100.0%) | 0.37% +0.367 pp | 0.01% +0.008 pp | USD76.49 +0.0% | 24 qtrs — |
| 54 | PARADIGM BIOCAPITAL ADVISORS LP | 684.3K +— (+0.0%) | 52.34M +16.8M (+47.3%) | 0.36% +0.000 pp | 1.34% +0.325 pp | USD43.18 +77.1% | 3 qtrs — |
| 55 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 638.9K +505.1K (+377.4%) | 48.87M +41.9M (+603.0%) | 0.34% +0.265 pp | 0.17% +0.148 pp | USD71.35 +7.2% | 2 qtrs — |
| 56 | GW&K INVESTMENT MANAGEMENT, LLC | 626.1K +27.9K (+4.7%) | 47.89M +16.8M (+54.1%) | 0.33% +0.015 pp | 0.41% +0.139 pp | USD53.03 +44.2% | 2 qtrs — |
| 57 | BARCLAYS PLC | 622.6K +77.6K (+14.2%) | 47.62M +33.7M (+243.2%) | 0.33% +0.041 pp | 0.01% +0.008 pp | USD39.36 +94.3% | 27 qtrs — |
| 58 | BANK OF NEW YORK MELLON CORP | 596.4K -331.4K (-35.7%) | 45.62M -2.6M (-5.3%) | 0.31% -0.174 pp | 0.01% -0.001 pp | USD42.38 +80.5% | 26 qtrs — |
| 59 | FIRST TURN MANAGEMENT, LLC | 595.5K +5.7K (+1.0%) | 45.55M +14.9M (+48.7%) | 0.31% +0.003 pp | 5.20% +0.605 pp | USD30.42 +151.4% | 6 qtrs — |
| 60 | FEDERATED HERMES, INC. | 586.8K +162.1K (+38.2%) | 44.88M +22.8M (+103.5%) | 0.31% +0.085 pp | 0.08% +0.036 pp | USD54.58 +40.1% | 3 qtrs — |
| 61 | VOYA INVESTMENT MANAGEMENT LLC | 583.4K +109.9K (+23.2%) | 44.62M +20.0M (+81.4%) | 0.31% +0.058 pp | 0.04% +0.019 pp | USD48.34 +58.2% | 25 qtrs — |
| 62 | PRIMECAP MANAGEMENT CO/CA/ | 569.7K -6.7K (-1.2%) | 43.57M +13.6M (+45.6%) | 0.30% -0.004 pp | 0.03% +0.010 pp | USD32.22 +137.4% | 20 qtrs — |
| 63 | EMERALD ADVISERS, LLC | 535.8K -184.6K (-25.6%) | 40.98M +3.6M (+9.5%) | 0.28% -0.097 pp | 1.26% +0.063 pp | USD22.51 +239.8% | 11 qtrs — |
| 64 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 508.1K -436.7K (-46.2%) | 38.87M -10.2M (-20.8%) | 0.27% -0.229 pp | 0.06% -0.019 pp | USD45.21 +69.2% | 8 qtrs — |
| 65 | CLEARBRIDGE INVESTMENTS, LLC | 498.3K +5.3K (+1.1%) | 38.12M +12.5M (+48.8%) | 0.26% +0.003 pp | 0.03% +0.011 pp | USD48.95 +56.3% | 3 qtrs — |
| 66 | NUVEEN, LLC | 494.8K -9.3K (-1.8%) | 37.85M +11.7M (+44.5%) | 0.26% -0.005 pp | 0.01% +0.003 pp | USD37.75 +102.6% | 4 qtrs — |
| 67 | GILDER GAGNON HOWE & CO LLC | 458.0K -4.3K (-0.9%) | 35.03M +11.0M (+45.9%) | 0.24% -0.002 pp | 0.37% +0.125 pp | USD42.04 +81.9% | 20 qtrs — |
| 68 | UBS ASSET MANAGEMENT AMERICAS INC | 451.0K -62.2K (-12.1%) | 34.50M +7.8M (+29.4%) | 0.24% -0.033 pp | 0.01% +0.002 pp | USD22.48 +240.3% | 27 qtrs — |
| 69 | RUSSELL INVESTMENTS GROUP, LTD. | 415.2K +31.7K (+8.3%) | 31.76M +11.8M (+59.4%) | 0.22% +0.017 pp | 0.03% +0.012 pp | USD43.25 +76.9% | 23 qtrs — |
| 70 | DIMENSIONAL FUND ADVISORS LP | 382.6K +314.3K (+460.5%) | 29.25M +25.7M (+725.1%) | 0.20% +0.165 pp | 0.01% +0.005 pp | USD68.36 +11.9% | 10 qtrs — |
| 71 | DEUTSCHE BANK AG\ | 381.1K -45.2K (-10.6%) | 29.15M +7.0M (+31.6%) | 0.20% -0.024 pp | 0.01% +0.002 pp | USD30.33 +152.2% | 26 qtrs — |
| 72 | EVENTIDE ASSET MANAGEMENT, LLC | 362.1K -222.2K (-38.0%) | 27.70M -2.6M (-8.7%) | 0.19% -0.117 pp | 0.43% -0.066 pp | USD28.69 +166.6% | 12 qtrs — |
| 73 | ALGERT GLOBAL LLC | 341.0K +226.2K (+196.9%) | 26.09M +20.1M (+337.3%) | 0.18% +0.119 pp | 0.41% +0.307 pp | USD66.56 +14.9% | 16 qtrs — |
| 74 | LEGAL & GENERAL GROUP PLC | 334.7K -4.8K (-1.4%) | 25.60M +8.0M (+45.2%) | 0.18% -0.003 pp | 0.01% +0.002 pp | USD43.29 +76.7% | 27 qtrs — |
| 75 | AFFINITY ASSET ADVISORS, LLC | 320.0K +255.0K (+392.3%) | 24.48M +21.1M (+625.0%) | 0.17% +0.134 pp | 1.39% +1.101 pp | USD66.87 +14.4% | 12 qtrs — |
| 76 | EMERALD MUTUAL FUND ADVISERS TRUST | 316.8K -94.6K (-23.0%) | 24.23M +2.9M (+13.4%) | 0.17% -0.050 pp | 1.18% +0.077 pp | USD21.26 +259.8% | 11 qtrs — |
| 77 | NOMURA HOLDINGS INC | 309.9K -122.2K (-28.3%) | 23.71M +1.3M (+5.6%) | 0.16% -0.064 pp | 0.03% -0.003 pp | USD39.87 +91.8% | 22 qtrs — |
| 78 | PFM HEALTH SCIENCES, LP | 306.5K -20.7K (-6.3%) | 23.44M +6.5M (+38.0%) | 0.16% -0.011 pp | 2.34% +1.031 pp | USD32.29 +136.9% | 5 qtrs — |
| 79 | WOODLINE PARTNERS LP | 300.9K +102.6K (+51.7%) | 23.02M +12.7M (+123.4%) | 0.16% +0.054 pp | 0.09% +0.041 pp | USD44.43 +72.2% | 13 qtrs — |
| 80 | NICHOLAS INVESTMENT PARTNERS, LP | 284.7K +13.1K (+4.8%) | 21.78M +7.7M (+54.3%) | 0.15% +0.007 pp | 1.59% +0.507 pp | USD41.66 +83.6% | 6 qtrs — |
| 81 | SWISS NATIONAL BANK | 282.6K +6.6K (+2.4%) | 21.62M +7.3M (+50.8%) | 0.15% +0.004 pp | 0.01% +0.005 pp | USD42.39 +80.4% | 20 qtrs — |
| 82 | FIRST TRUST ADVISORS LP | 281.7K +36.2K (+14.7%) | 21.55M +8.8M (+69.0%) | 0.15% +0.019 pp | 0.02% +0.006 pp | USD44.96 +70.1% | 4 qtrs — |
| 83 | ARTISAN PARTNERS LIMITED PARTNERSHIP | 279.1K -52.2K (-15.8%) | 21.35M +4.1M (+24.0%) | 0.15% -0.027 pp | 0.03% +0.008 pp | USD35.25 +117.0% | 4 qtrs — |
| 84 | CANDRIAM S.C.A. | 278.9K +129.9K (+87.2%) | 21.33M +13.6M (+175.7%) | 0.15% +0.068 pp | 0.11% +0.066 pp | USD63.38 +20.7% | 2 qtrs — |
| 85 | VICTORY CAPITAL MANAGEMENT INC | 277.1K -202.6K (-42.2%) | 21.19M -3.7M (-14.9%) | 0.15% -0.106 pp | 0.01% -0.003 pp | USD42.22 +81.2% | 27 qtrs — |
| 86 | SQUAREPOINT OPS LLC | 268.9K +268.9K (+100.0%) | 20.57M +20.6M (+100.0%) | 0.14% +0.141 pp | 0.02% +0.022 pp | USD76.49 +0.0% | 1 qtrs NEW |
| 87 | EAGLE HEALTH INVESTMENTS LP | 259.3K +— (+0.0%) | 19.83M +6.4M (+47.3%) | 0.14% +0.000 pp | 4.36% +0.823 pp | USD43.18 +77.1% | 3 qtrs — |
| 88 | ADVISOR GROUP HOLDINGS, INC. | 252.1K -7.9K (-3.0%) | 19.29M +5.8M (+42.8%) | 0.13% -0.004 pp | 0.03% +0.009 pp | USD51.77 +47.7% | 24 qtrs — |
| 89 | SKANDINAVISKA ENSKILDA BANKEN AB (PUBL) | 237.8K +88.9K (+59.7%) | 18.19M +10.5M (+135.2%) | 0.12% +0.047 pp | 0.07% +0.042 pp | USD55.42 +38.0% | 10 qtrs — |
| 90 | BALYASNY ASSET MANAGEMENT L.P. | 234.4K -780.3K (-76.9%) | 17.93M -34.8M (-66.0%) | 0.12% -0.410 pp | 0.02% -0.044 pp | USD38.98 +96.2% | 7 qtrs — |
| 91 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 233.9K +11.6K (+5.2%) | 17.89M +6.3M (+55.0%) | 0.12% +0.006 pp | 0.03% +0.010 pp | USD39.08 +95.7% | 4 qtrs — |
| 92 | ROYCE & ASSOCIATES LP | 232.9K +— (+0.0%) | 17.82M +5.7M (+47.3%) | 0.12% +0.000 pp | 0.18% +0.060 pp | USD31.02 +146.6% | 6 qtrs — |
| 93 | FISHER ASSET MANAGEMENT, LLC | 232.4K +232.4K (+100.0%) | 17.78M +17.8M (+100.0%) | 0.12% +0.122 pp | 0.01% +0.006 pp | USD76.49 +0.0% | 1 qtrs NEW |
| 94 | WELLS FARGO & COMPANY/MN | 232.3K +83.1K (+55.8%) | 17.77M +10.0M (+129.4%) | 0.12% +0.044 pp | 0.00% +0.002 pp | USD52.13 +46.7% | 26 qtrs — |
| 95 | BROOKLANDS FUND MANAGEMENT LTD | 2.75M +2.8M (+100.0%) | 2.81M +2.8M (+100.0%) | 1.44% +1.443 pp | 1.32% +1.322 pp | USD76.49 +0.0% | 1 qtrs NEW |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.18
Bearish
Ratio by volume
0.63
Neutral
Buys
11
Sells
60
Shares acquired
391.9K
Shares disposed
621.2K
Cash buys
—
Cash sales
50.00
Net activity
-229,283
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-30 | Apuli Maricel | Officer | S-Sale | D | Common Stock | 2,000 | 71.58 | 143.2K | 134,115 | D | ↗ |
| 2026-04-10 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 20,000 | 74.60 | 1.49M | 4,398,447 | I | ↗ |
| 2026-04-09 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 7,072 | 73.64 | 520.8K | 4,431,375 | I | ↗ |
| 2026-03-18 | Trimarchi Thomas | Officer | A-Award | A | Common Stock | 59,041 | 0.00 | — | 395,626 | D | ↗ |
| 2026-03-18 | Apuli Maricel | Officer | A-Award | A | Common Stock | 14,170 | 0.00 | — | 136,115 | D | ↗ |
| 2026-03-17 | Kumar Neil | Director / Officer | A-Award | A | Restricted Stock Units | 104,313 | 0.00 | — | 104,313 | D | ↗ |
| 2026-03-13 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 9,759 | 69.23 | 675.6K | 4,438,447 | I | ↗ |
| 2026-03-12 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 14,337 | 68.48 | 981.8K | 661,349 | I | ↗ |
| 2026-03-10 | Valantine Hannah | Director | S-Sale | D | Common Stock | 8,671 | 72.00 | 624.3K | 7,465 | D | ↗ |
| 2026-03-04 | Ellis Andrea | Director | M-Exempt | A | Common Stock | 64,921 | 8.45 | 548.6K | 83,510 | D | ↗ |
| 2026-02-27 | Valantine Hannah | Director | M-Exempt | D | Stock Option (Right to Buy) | 25,484 | 48.45 | 1.23M | 0 | D | ↗ |
| 2026-02-26 | Apuli Maricel | Officer | S-Sale | D | Common Stock | 2,000 | 66.00 | 132.0K | 121,945 | D | ↗ |
| 2026-02-19 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 602 | 72.80 | 43.8K | 234,451 | D | ↗ |
| 2026-02-17 | Trimarchi Thomas | Officer | S-Sale | D | Common Stock | 200 | 75.38 | 15.1K | 336,585 | D | ↗ |
| 2026-02-17 | Scott Randal W. | Director | S-Sale | D | Common Stock | 3,307 | 75.93 | 251.1K | 11,589 | D | ↗ |
| 2026-02-17 | Apuli Maricel | Officer | S-Sale | D | Common Stock | 510 | 74.31 | 37.9K | 123,945 | D | ↗ |
| 2026-02-16 | Trimarchi Thomas | Officer | F-InKind | D | Common Stock | 18,819 | 75.25 | 1.42M | 350,185 | D | ↗ |
| 2026-02-16 | Kumar Neil | Director / Officer | M-Exempt | A | Common Stock | 33,544 | 0.00 | — | 262,320 | D | ↗ |
| 2026-02-16 | Apuli Maricel | Officer | F-InKind | D | Common Stock | 4,349 | 75.25 | 327.3K | 124,455 | D | ↗ |
| 2026-02-11 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 3,994 | 73.25 | 292.6K | 675,686 | I | ↗ |
| 2026-02-10 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 5,960 | 72.27 | 430.8K | 4,498,447 | I | ↗ |
| 2026-01-09 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 6,955 | 76.72 | 533.6K | 726,580 | I | ↗ |
| 2026-01-08 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 8,085 | 74.38 | 601.3K | 736,086 | I | ↗ |
| 2025-12-15 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 1,700 | 75.24 | 127.9K | 228,776 | D | ↗ |
| 2025-12-12 | Trimarchi Thomas | Officer | F-InKind | D | Common Stock | 13,826 | 75.15 | 1.04M | 369,004 | D | ↗ |
| 2025-12-12 | Kumar Neil | Director / Officer | F-InKind | D | Common Stock | 30,964 | 75.15 | 2.33M | 258,787 | D | ↗ |
| 2025-12-12 | Apuli Maricel | Officer | F-InKind | D | Common Stock | 2,003 | 75.15 | 150.5K | 128,294 | D | ↗ |
| 2025-12-08 | Apuli Maricel | Officer | S-Sale | D | Common Stock | 2,000 | 74.26 | 148.5K | 130,297 | D | ↗ |
| 2025-12-05 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 12,517 | 73.05 | 914.3K | 763,169 | I | ↗ |
| 2025-12-04 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 12,192 | 74.42 | 907.4K | 781,394 | I | ↗ |
| 2025-11-20 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 6,401 | 64.97 | 415.9K | 248,531 | D | ↗ |
| 2025-11-18 | Lo Andrew | Director | S-Sale | D | Common Stock | 24,007 | 65.23 | 1.57M | 81,576 | I | ↗ |
| 2025-11-17 | Trimarchi Thomas | Officer | S-Sale | D | Common Stock | 6,956 | 66.84 | 464.9K | 382,830 | D | ↗ |
| 2025-11-17 | Scott Randal W. | Director | S-Sale | D | Common Stock | 6,199 | 66.89 | 414.7K | 11,589 | D | ↗ |
| 2025-11-17 | Lo Andrew | Director | S-Sale | D | Common Stock | 3,798 | 67.06 | 254.7K | 14,089 | D | ↗ |
| 2025-11-16 | Trimarchi Thomas | Officer | F-InKind | D | Common Stock | 21,317 | 66.39 | 1.42M | 399,764 | D | ↗ |
| 2025-11-16 | Kumar Neil | Director / Officer | M-Exempt | D | Restricted Stock Units | 33,544 | 0.00 | — | 167,720 | D | ↗ |
| 2025-11-16 | Apuli Maricel | Officer | F-InKind | D | Common Stock | 4,781 | 66.39 | 317.4K | 132,297 | D | ↗ |
| 2025-11-12 | Valantine Hannah | Director | M-Exempt | D | Stock Option (Right to Buy) | 25,484 | 48.45 | 1.23M | 25,484 | D | ↗ |
| 2025-11-07 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 12,234 | 61.13 | 747.9K | 803,452 | I | ↗ |
| 2025-11-06 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 12,576 | 62.91 | 791.2K | 4,625,871 | I | ↗ |
| 2025-11-06 | DANIELS RONALD J | Director | S-Sale | D | Common Stock | 61,031 | 63.72 | 3.89M | 16,991 | D | ↗ |
| 2025-10-29 | MCCORMICK FRANK | Director | S-Sale | D | Common Stock | 3,497 | 67.52 | 236.1K | 731,970 | I | ↗ |
| 2025-10-27 | MCCORMICK FRANK | Director | S-Sale | D | Common Stock | 1,641 | 65.00 | 106.7K | 878,338 | I | ↗ |
| 2025-10-09 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 20,000 | 54.80 | 1.10M | 4,638,447 | I | ↗ |
| 2025-10-08 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 8,706 | 54.39 | 473.5K | 4,669,741 | I | ↗ |
| 2025-09-05 | MCCORMICK FRANK | Director | S-Sale | D | Common Stock | 74,000 | 53.16 | 3.93M | 83,275 | D | ↗ |
| 2025-09-05 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 2,300 | 51.95 | 119.5K | 4,696,147 | I | ↗ |
| 2025-09-04 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 5,475 | 51.85 | 283.9K | 4,698,447 | I | ↗ |
| 2025-08-21 | Trimarchi Thomas | Officer | S-Sale | D | Common Stock | 42,237 | 49.48 | 2.09M | 421,081 | D | ↗ |
| 2025-08-20 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 25,728 | 48.81 | 1.26M | 223,518 | D | ↗ |
| 2025-08-18 | Trimarchi Thomas | Officer | S-Sale | D | Common Stock | 15,380 | 50.14 | 771.2K | 465,291 | D | ↗ |
| 2025-08-16 | Trimarchi Thomas | Officer | F-InKind | D | Common Stock | 21,317 | 51.32 | 1.09M | 480,671 | D | ↗ |
| 2025-08-16 | Kumar Neil | Director / Officer | M-Exempt | A | Common Stock | 64,697 | 0.00 | — | 282,101 | D | ↗ |
| 2025-08-16 | Apuli Maricel | Officer | F-InKind | D | Common Stock | 4,781 | 51.32 | 245.4K | 137,078 | D | ↗ |
| 2025-08-11 | HOMCY CHARLES J | Director | S-Sale | D | Common Stock | 50,000 | 48.00 | 2.40M | 916,674 | D | ↗ |
| 2025-08-08 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 8,205 | 46.71 | 383.3K | 915,686 | I | ↗ |
| 2025-08-08 | HOMCY CHARLES J | Director | S-Sale | D | Common Stock | 191,662 | 45.87 | 8.79M | 1,025,012 | D | ↗ |
| 2025-08-07 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 6,784 | 45.09 | 305.9K | 948,902 | I | ↗ |
| 2025-08-07 | Apuli Maricel | Officer | S-Sale | D | Common Stock | 1,000 | 45.44 | 45.4K | 141,859 | D | ↗ |
| 2025-08-05 | Ellis Andrea | Director | M-Exempt | A | Common Stock | 17,167 | 16.75 | 287.5K | 35,756 | D | ↗ |
| 2025-07-02 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 20,000 | 42.73 | 854.5K | 4,758,447 | I | ↗ |
| 2025-07-01 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 18,300 | 42.50 | 777.8K | 4,780,147 | I | ↗ |
| 2025-06-27 | VIKING GLOBAL INVESTORS LP | 10% Owner | S-Sale | D | Common Stock | 3,500,000 | 44.00 | 154.00M | 18,555,375 | I | ↗ |
| 2025-06-27 | HOMCY CHARLES J | Director | G-Gift | D | Common Stock | 20,000 | 0.00 | — | 1,216,674 | D | ↗ |
| 2025-06-26 | Valantine Hannah | Director | S-Sale | D | Common Stock | 1,891 | 44.03 | 83.3K | 398 | I | ↗ |
| 2025-06-24 | MCCORMICK FRANK | Director | S-Sale | D | Common Stock | 100,000 | 44.23 | 4.42M | 879,979 | I | ↗ |
| 2025-06-20 | Valantine Hannah | Director | A-Award | A | Common Stock | 6,589 | 0.00 | — | 8,353 | D | ↗ |
| 2025-06-20 | Scott Randal W. | Director | A-Award | A | Stock Option (Right to Buy) | 8,425 | 41.73 | 351.6K | 8,425 | D | ↗ |
| 2025-06-20 | Satvat Ali J. | Director | A-Award | A | Stock Option (Right to Buy) | 8,425 | 41.73 | 351.6K | 8,425 | D | ↗ |
| 2025-06-20 | MOMTAZEE JAMES C | Director | A-Award | A | Stock Option (Right to Buy) | 8,425 | 41.73 | 351.6K | 8,425 | D | ↗ |
| 2025-06-20 | MCCORMICK FRANK | Director | A-Award | A | Stock Option (Right to Buy) | 8,425 | 41.73 | 351.6K | 8,425 | D | ↗ |
| 2025-06-20 | Lo Andrew | Director | A-Award | A | Stock Option (Right to Buy) | 8,425 | 41.73 | 351.6K | 8,425 | D | ↗ |
| 2025-06-20 | Hassan Fred | Director | A-Award | A | Stock Option (Right to Buy) | 8,425 | 41.73 | 351.6K | 8,425 | D | ↗ |
| 2025-06-20 | HOMCY CHARLES J | Director | A-Award | A | Stock Option (Right to Buy) | 8,425 | 41.73 | 351.6K | 8,425 | D | ↗ |
| 2025-06-20 | Ellis Andrea | Director | A-Award | A | Stock Option (Right to Buy) | 8,425 | 41.73 | 351.6K | 8,425 | D | ↗ |
| 2025-06-20 | Dachille Douglas A. | Director | A-Award | A | Common Stock | 6,589 | 0.00 | — | 6,589 | D | ↗ |
| 2025-06-20 | DANIELS RONALD J | Director | A-Award | A | Common Stock | 6,589 | 0.00 | — | 16,991 | D | ↗ |
| 2025-06-20 | Cook Jennifer E. | Director | A-Award | A | Stock Option (Right to Buy) | 8,425 | 41.73 | 351.6K | 8,425 | D | ↗ |
| 2025-06-20 | AGUIAR ERIC | Director | A-Award | A | Common Stock | 6,589 | 0.00 | — | 6,589 | D | ↗ |
| 2025-06-10 | Valantine Hannah | Director | S-Sale | D | Common Stock | 4,292 | 40.00 | 171.7K | 1,764 | D | ↗ |
| 2025-05-20 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 75,000 | 33.40 | 2.50M | 4,798,447 | I | ↗ |
| 2025-05-19 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 25,756 | 33.32 | 858.3K | 217,804 | D | ↗ |
| 2025-05-16 | Trimarchi Thomas | Officer | F-InKind | D | Common Stock | 21,317 | 33.84 | 721.4K | 501,988 | D | ↗ |
| 2025-05-16 | Kumar Neil | Director / Officer | M-Exempt | A | Common Stock | 64,696 | 0.00 | — | 276,414 | D | ↗ |
| 2025-05-16 | Apuli Maricel | Officer | F-InKind | D | Common Stock | 4,780 | 33.84 | 161.8K | 142,859 | D | ↗ |
| 2025-05-12 | KKR Genetic Disorder L.P. | 10% Owner | S-Sale | D | Common Stock | 6,000,000 | 34.20 | 205.20M | 13,260,971 | I | ↗ |
| 2025-05-08 | MCCORMICK FRANK | Director | G-Gift | D | Common Stock | 3,000 | 0.00 | — | 76,686 | D | ↗ |
| 2025-05-07 | MCCORMICK FRANK | Director | G-Gift | D | Common Stock | 33,000 | 0.00 | — | 79,686 | D | ↗ |
| 2025-05-02 | Lo Andrew | Director | S-Sale | D | Common Stock | 100,000 | 38.50 | 3.85M | 105,583 | I | ↗ |
| 2025-05-02 | Apuli Maricel | Officer | S-Sale | D | Common Stock | 1,026 | 38.51 | 39.5K | 147,639 | D | ↗ |
| 2025-04-22 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 75,000 | 34.11 | 2.56M | 4,873,447 | I | ↗ |
| 2025-04-14 | Ellis Andrea | Director | M-Exempt | D | Stock Option (right to buy) | 10,000 | 8.45 | 84.5K | 64,921 | D | ↗ |
| 2025-04-01 | Ellis Andrea | Director | M-Exempt | D | Stock Option (right to buy) | 30,000 | 8.45 | 253.5K | 74,921 | D | ↗ |
| 2025-03-25 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 75,000 | 36.87 | 2.76M | 4,948,447 | I | ↗ |
| 2025-03-19 | Trimarchi Thomas | Officer | A-Award | A | Common Stock | 109,100 | 0.00 | — | 523,305 | D | ↗ |
| 2025-03-19 | Kumar Neil | Director / Officer | A-Award | A | Restricted Stock Units | 184,860 | 0.00 | — | 184,860 | D | ↗ |
| 2025-03-19 | Apuli Maricel | Officer | A-Award | A | Common Stock | 23,660 | 0.00 | — | 148,665 | D | ↗ |
| 2025-03-06 | Valantine Hannah | Director | S-Sale | D | Common Stock | 12,875 | 32.58 | 419.5K | 1,764 | D | ↗ |
| 2025-03-05 | KKR Genetic Disorder L.P. | 10% Owner | S-Sale | D | Common Stock | 6,000,000 | 32.96 | 197.76M | 19,260,971 | I | ↗ |
| 2025-02-25 | STEPHENSON BRIAN C | Officer | M-Exempt | D | Stock Option (right to buy) | 8,500 | 17.00 | 144.5K | 440,170 | D | ↗ |
| 2025-02-25 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 37,899 | 33.36 | 1.26M | 5,060,548 | I | ↗ |
| 2025-02-19 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 4,148 | 36.16 | 150.0K | 102,464 | D | ↗ |
| 2025-02-19 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 76 | 36.56 | 2.8K | 211,718 | D | ↗ |
| 2025-02-19 | Apuli Maricel | Officer | — | — | Common Stock | 0 | 0.00 | — | 125,005 | D | ↗ |
| 2025-02-16 | Trimarchi Thomas | Officer | F-InKind | D | Common Stock | 13,782 | 34.90 | 481.0K | 414,205 | D | ↗ |
| 2025-02-16 | STEPHENSON BRIAN C | Officer | M-Exempt | D | Restricted Stock Units | 6,705 | 0.00 | — | 80,459 | D | ↗ |
| 2025-02-16 | Kumar Neil | Director / Officer | F-InKind | D | Common Stock | 23,996 | 34.90 | 837.5K | 243,261 | D | ↗ |
| 2025-01-31 | VIKING GLOBAL INVESTORS LP | 10% Owner | S-Sale | D | Common Stock | 3,065,616 | 34.90 | 106.99M | 22,055,375 | I | ↗ |
| 2025-01-29 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 269,068 | 36.34 | 9.78M | 5,102,447 | I | ↗ |
| 2025-01-28 | STEPHENSON BRIAN C | Officer | M-Exempt | D | Stock Option (right to buy) | 68,000 | 17.00 | 1.16M | 448,670 | D | ↗ |
| 2025-01-28 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 326,932 | 36.29 | 11.86M | 5,371,515 | I | ↗ |
| 2024-12-30 | Satvat Ali J. | Director | M-Exempt | D | Stock Option (Right to Buy) | 79,702 | 10.99 | 875.9K | 0 | D | ↗ |
| 2024-12-26 | MCCORMICK FRANK | Director | G-Gift | D | Common Stock | 7,400 | 0.00 | — | 112,686 | D | ↗ |
| 2024-12-24 | Kumar Neil | Director / Officer | G-Gift | A | Common Stock | 4,685,725 | 0.00 | — | 5,698,447 | I | ↗ |
| 2024-12-10 | Trimarchi Thomas | Officer | A-Award | A | Common Stock | 50,000 | 0.00 | — | 427,987 | D | ↗ |
| 2024-12-10 | STEPHENSON BRIAN C | Officer | A-Award | A | Restricted Stock Units | 42,683 | 0.00 | — | 42,683 | D | ↗ |
| 2024-12-10 | Kumar Neil | Director / Officer | A-Award | A | Restricted Stock Units | 121,951 | 0.00 | — | 121,951 | D | ↗ |
| 2024-11-19 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 4,156 | 22.41 | 93.1K | 93,758 | D | ↗ |
| 2024-11-19 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 25,514 | 22.39 | 571.1K | 4,899,318 | D | ↗ |
| 2024-11-16 | Trimarchi Thomas | Officer | F-InKind | D | Common Stock | 17,936 | 23.72 | 425.4K | 377,987 | D | ↗ |
| 2024-11-16 | STEPHENSON BRIAN C | Officer | M-Exempt | D | Restricted Stock Units | 6,705 | 0.00 | — | 87,164 | D | ↗ |
| 2024-11-16 | Kumar Neil | Director / Officer | M-Exempt | D | Restricted Stock Units | 19,599 | 0.00 | — | 254,791 | D | ↗ |
| 2024-09-13 | KKR Genetic Disorder L.P. | 10% Owner | S-Sale | D | Common Stock | 5,800,000 | 25.75 | 149.35M | 25,260,971 | — | ↗ |
| 2024-08-19 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 2,457 | 24.39 | 59.9K | 86,890 | — | ↗ |
| 2024-08-19 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 16,192 | 24.39 | 394.9K | 4,897,443 | — | ↗ |
| 2024-08-16 | Trimarchi Thomas | Officer | F-InKind | D | Common Stock | 17,936 | 24.40 | 437.6K | 395,923 | — | ↗ |
| 2024-08-16 | STEPHENSON BRIAN C | Officer | M-Exempt | A | Common Stock | 25,797 | 0.00 | — | 102,424 | — | ↗ |
| 2024-08-16 | Kumar Neil | Director / Officer | M-Exempt | D | Restricted Stock Units | 2,394 | 0.00 | — | 4,789 | — | ↗ |
| 2024-08-06 | Trimarchi Thomas | Officer | A-Award | A | Common Stock | 19,003 | 0.00 | — | 413,859 | — | ↗ |
| 2024-07-23 | Trimarchi Thomas | Officer | — | D | Common Stock | 0 | 0.00 | — | 394,856 | — | ↗ |
| 2024-06-21 | Valantine Hannah | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | Scott Randal W. | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | Satvat Ali J. | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | MOMTAZEE JAMES C | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | MCCORMICK FRANK | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | Lo Andrew | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | Hassan Fred | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | HOMCY CHARLES J | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | Ellis Andrea | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | Dachille Douglas A. | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | DANIELS RONALD J | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | Cook Jennifer E. | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-21 | AGUIAR ERIC | Director | A-Award | A | Stock Option (Right to Buy) | 26,014 | 27.36 | 711.7K | 26,014 | — | ↗ |
| 2024-06-04 | Scott Randal W. | Director | S-Sale | D | Common Stock | 1,500 | 31.30 | 47.0K | 4,000 | — | ↗ |
| 2024-06-03 | Scott Randal W. | Director | S-Sale | D | Common Stock | 800 | 28.68 | 22.9K | 5,700 | — | ↗ |
| 2024-05-16 | STEPHENSON BRIAN C | Officer | M-Exempt | D | Restricted Stock Units | 1,710 | 0.00 | — | 0 | — | ↗ |
| 2024-05-16 | Kumar Neil | Director / Officer | M-Exempt | D | Restricted Stock Units | 5,130 | 0.00 | — | 0 | — | ↗ |
| 2024-03-12 | STEPHENSON BRIAN C | Officer | A-Award | A | Stock Option (right to buy) | 15,442 | 28.70 | 443.2K | 15,442 | — | ↗ |
| 2024-03-12 | Kumar Neil | Director / Officer | A-Award | A | Restricted Stock Units | 313,588 | 0.00 | — | 313,588 | — | ↗ |
| 2024-03-01 | Scott Randal W. | Director | S-Sale | D | Common Stock | 2,500 | 34.00 | 85.0K | 6,500 | — | ↗ |
| 2024-02-16 | STEPHENSON BRIAN C | Officer | M-Exempt | D | Restricted Stock Units | 24,193 | 0.00 | — | 0 | — | ↗ |
| 2024-02-16 | Kumar Neil | Director / Officer | M-Exempt | D | Restricted Stock Units | 61,182 | 0.00 | — | 0 | — | ↗ |
| 2024-02-16 | HOMCY CHARLES J | Director | F-InKind | D | Common Stock | 1,509 | 37.21 | 56.1K | 1,230,085 | — | ↗ |
| 2024-02-15 | Valantine Hannah | Director | M-Exempt | D | Stock Option (right to buy) | 2,915 | 8.45 | 24.6K | 93,261 | — | ↗ |
| 2024-01-16 | Valantine Hannah | Director | S-Sale | D | Common Stock | 2,915 | 37.97 | 110.7K | 1,764 | — | ↗ |
| 2023-12-31 | Valantine Hannah | Director | — | D | Common Stock | 0 | 0.00 | — | 1,764 | — | ↗ |
| 2023-12-26 | MCCORMICK FRANK | Director | S-Sale | D | Common Stock | 100,000 | 42.06 | 4.21M | 627,689 | — | ↗ |
| 2023-12-18 | Scott Randal W. | Director | S-Sale | D | Common Stock | 2,000 | 40.00 | 80.0K | 9,000 | — | ↗ |
| 2023-12-15 | Valantine Hannah | Director | M-Exempt | D | Stock Option (right to buy) | 2,915 | 8.45 | 24.6K | 99,091 | — | ↗ |
| 2023-12-01 | Scott Randal W. | Director | S-Sale | D | Common Stock | 1,000 | 28.50 | 28.5K | 12,500 | — | ↗ |
| 2023-11-17 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 22,685 | 29.10 | 660.1K | 36,710 | — | ↗ |
| 2023-11-17 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 51,352 | 29.10 | 1.49M | 4,813,397 | — | ↗ |
| 2023-11-16 | STEPHENSON BRIAN C | Officer | M-Exempt | D | Restricted Stock Units | 778 | 0.00 | — | 3,891 | — | ↗ |
| 2023-11-16 | Kumar Neil | Director / Officer | M-Exempt | D | Restricted Stock Units | 5,129 | 0.00 | — | 10,259 | — | ↗ |
| 2023-11-16 | HOMCY CHARLES J | Director | F-InKind | D | Common Stock | 1,301 | 28.86 | 37.5K | 1,226,996 | — | ↗ |
| 2023-11-15 | Valantine Hannah | Director | M-Exempt | A | Common Stock | 2,915 | 8.45 | 24.6K | 4,679 | — | ↗ |
| 2023-09-05 | Scott Randal W. | Director | S-Sale | D | Common Stock | 2,500 | 30.00 | 75.0K | 13,500 | — | ↗ |
| 2023-08-17 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 22,683 | 28.59 | 648.5K | 36,710 | — | ↗ |
| 2023-08-17 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 51,552 | 28.59 | 1.47M | 4,813,197 | — | ↗ |
| 2023-08-16 | STEPHENSON BRIAN C | Officer | M-Exempt | D | Restricted Stock Units | 1,709 | 0.00 | — | 5,130 | — | ↗ |
| 2023-08-16 | Kumar Neil | Director / Officer | M-Exempt | D | Restricted Stock Units | 2,394 | 0.00 | — | 14,365 | — | ↗ |
| 2023-08-16 | HOMCY CHARLES J | Director | M-Exempt | D | Restricted Stock Units | 3,760 | 0.00 | — | 7,520 | — | ↗ |
| 2023-07-18 | VIKING GLOBAL INVESTORS LP | 10% Owner | S-Sale | D | Common Stock | 1,500,000 | 35.00 | 52.50M | 25,120,991 | — | ↗ |
| 2023-06-21 | Valantine Hannah | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | Scott Randal W. | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | Satvat Ali J. | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | MOMTAZEE JAMES C | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | Lo Andrew | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | Hassan Fred | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | HOMCY CHARLES J | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | Ellis Andrea | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | Dachille Douglas A. | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | DANIELS RONALD J | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | Cook Jennifer E. | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-06-21 | AGUIAR ERIC | Director | A-Award | A | Stock Option (right to buy) | 51,501 | 16.75 | 862.6K | 51,501 | — | ↗ |
| 2023-05-17 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 24,424 | 14.01 | 342.2K | 36,408 | — | ↗ |
| 2023-05-17 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 51,552 | 14.01 | 722.2K | 4,813,197 | — | ↗ |
| 2023-05-16 | STEPHENSON BRIAN C | Officer | M-Exempt | D | Restricted Stock Units | 778 | 0.00 | — | 5,447 | — | ↗ |
| 2023-05-16 | Kumar Neil | Director / Officer | M-Exempt | D | Restricted Stock Units | 2,394 | 0.00 | — | 16,759 | — | ↗ |
| 2023-05-16 | HOMCY CHARLES J | Director | M-Exempt | D | Restricted Stock Units | 3,759 | 0.00 | — | 11,280 | — | ↗ |
| 2023-05-03 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 64,929 | 14.18 | 920.7K | 36,408 | — | ↗ |
| 2023-05-03 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 120,000 | 14.18 | 1.70M | 1,012,722 | — | ↗ |
| 2023-04-05 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 55,500 | 15.45 | 857.7K | 101,337 | — | ↗ |
| 2023-04-05 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 120,000 | 15.46 | 1.86M | 1,132,722 | — | ↗ |
| 2023-03-03 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 62,692 | 10.96 | 687.1K | 156,837 | — | ↗ |
| 2023-03-03 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 120,000 | 10.96 | 1.32M | 1,252,722 | — | ↗ |
| 2023-02-21 | MCCORMICK FRANK | Director | — | D | Stock Option (right to buy) | 265,463 | 17.00 | 4.51M | 0 | — | ↗ |
| 2023-02-17 | STEPHENSON BRIAN C | Officer | S-Sale | D | Common Stock | 15,567 | 12.65 | 197.0K | 221,679 | — | ↗ |
| 2023-02-17 | Kumar Neil | Director / Officer | S-Sale | D | Common Stock | 44,798 | 12.70 | 569.1K | 4,813,197 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-940.5K
Shares Outstanding
193.86M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Neil Kumar, Ph.D. Chief Executive Officer | 1.04M | 1.40M | 10.61M | 1.87M | — | 15.3K | 14.94M | 83.52% | ↗ |
| 2 | 2025 | Thomas Trimarchi, Ph.D. President and Chief Financial Officer | 675.6K | 525.0K | 4.60M | — | — | 29.3K | 5.83M | 78.91% | ↗ |
| 3 | 2025 | Brian Stephenson, Ph.D., CFA Former Chief Financial Officer | 156.4K | — | — | — | — | 528.2K | 684.7K | 0.00% | ↗ |
| 4 | 2024 | Neil Kumar, Ph.D. Chief Executive Officer | 987.5K | 1.04M | 12.54M | 1,000.0K | — | 14.2K | 15.58M | 86.90% | ↗ |
| 5 | 2024 | Thomas Trimarchi, Ph.D. President and Chief Financial Officer | 643.7K | 454.2K | 5.32M | 60.6K | — | 27.6K | 6.50M | 82.69% | ↗ |
| 6 | 2024 | Brian Stephenson, Ph.D., CFA Former Chief Financial Officer | 661.0K | 328.0K | 4.32M | 342.1K | — | 14.2K | 5.66M | 82.29% | ↗ |
| 7 | 2023 | Neil Kumar, Ph.D. Chief Executive Officer | 742.0K | 779.1K | 6.12M | 4.50M | — | 13.7K | 12.16M | 87.38% | ↗ |
| 8 | 2023 | Brian Stephenson, Ph.D., CFA Chief Financial Officer | 650.0K | 487.5K | 3.17M | 2.33M | — | 13.7K | 6.65M | 82.69% | ↗ |
| 9 | 2023 | Brian Stephenson, Ph.D., CFA Former Chief Financial Officer | 650.0K | 487.5K | 3.17M | 2.33M | — | 13.7K | 6.65M | 82.69% | ↗ |
| 10 | 2022 | Neil Kumar, Ph.D. Chief Executive Officer | 1.11M | 940.1K | 4.57M | — | — | 56.8K | 6.67M | 68.49% | ↗ |
| 11 | 2022 | Brian Stephenson, Ph.D., CFA Chief Financial Officer | 650.0K | 487.5K | 1.81M | — | — | 12.2K | 2.96M | 61.12% | ↗ |
| 12 | 2022 | Brian Stephenson, Ph.D., CFA Former Chief Financial Officer | 650.0K | 487.5K | 1.81M | — | — | 12.2K | 2.96M | 61.12% | ↗ |
| 13 | 2021 | Neil Kumar, Ph.D. Chief Executive Officer | 725.0K | — | 2.64M | 22.23M | — | 32.9K | 25.63M | 97.04% | ↗ |
| 14 | 2021 | Brian Stephenson, Ph.D., CFA Chief Financial Officer | 600.0K | 225.0K | 1.44M | 6.40M | — | 11.6K | 8.68M | 90.36% | ↗ |
| 15 | 2020 | Neil Kumar, Ph.D. Chief Executive Officer | 550.0K | 825.0K | 2.37M | 6.30M | — | 11.4K | 10.05M | 86.21% | ↗ |
| 16 | 2020 | Michael Henderson, M.D. Chief Business Officer | 515.0K | 300.0K | 7.07M | 91.9K | — | 11.8K | 7.99M | 89.65% | ↗ |
| 17 | 2020 | Brian Stolz Chief Operating Officer | 511.4K | 25.0K | 736.9K | 1.99M | — | 1.98M | 5.24M | 52.07% | ↗ |
| 18 | 2020 | Cameron Turtle, Ph.D. Chief Strategy Officer | 400.0K | 210.0K | 3.94M | — | — | 11.4K | 4.56M | 86.38% | ↗ |
| 19 | 2020 | Brian Stephenson, Ph.D., CFA Chief Financial Officer | 550.0K | 712.5K | 789.5K | 2.10M | — | 11.9K | 4.16M | 69.39% | ↗ |
| 20 | 2020 | Charles Homcy, M.D. Chairman of Pharmaceuticals | 500.0K | 100.0K | — | 1.20M | — | 55.8K | 1.86M | 64.66% | ↗ |
| 21 | 2019 | Neil Kumar, Ph.D. Chief Executive Officer | 502.8K | 360.0K | 13.86M | 11.57M | — | 34.8K | 26.33M | 96.59% | ↗ |
| 22 | 2019 | Neil Kumar, M.D. Chief Executive Officer | 502.8K | 360.0K | 13.86M | 11.57M | — | 34.8K | 26.33M | 96.59% | ↗ |
| 23 | 2019 | Brian Stolz Chief Operating Officer | 146.8K | 93.8K | 6.86M | 1.05M | — | — | 8.15M | 97.05% | ↗ |
| 24 | 2019 | Charles Homcy, M.D. Chairman of Pharmaceuticals | 513.8K | — | 2.11M | 3.13M | — | 221.7K | 5.98M | 87.69% | ↗ |
| 25 | 2019 | Brian Stephenson, Ph.D., CFA Chief Financial Officer | 420.0K | 189.0K | 132.6K | 3.43M | — | 26.6K | 4.20M | 84.86% | ↗ |
| 26 | 2018 | Brian Stephenson, Ph.D., CFA Chief Financial Officer | 74.4K | 330.2K | 1.94M | — | — | — | 2.35M | 82.76% | ↗ |
| 27 | 2018 | Neil Kumar, Ph.D. Chief Executive Officer | 450.0K | — | — | — | — | — | 450.0K | 0.00% | ↗ |
| 28 | 2018 | Neil Kumar, M.D. Chief Executive Officer | 450.0K | — | — | — | — | — | 450.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Neil Kumar | Co-Founder, Chief Executive Officer & Director | 2M | — |
| Uma Sinha | Chief Scientific Officer | 1M | — |
| Thomas Trimarchi | Chief Financial Officer & President | 1M | — |
| Charles J. Homcy | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director | 574.2K | — |
| Frank McCormick | Co-Founder, Chairman of Oncology & Director | 550.0K | — |
| Richard H. Scheller | Chairman of Research & Development | 509.6K | — |
| Maricel Apuli | Chief Accounting Officer | — | female |
| Eli Wallace | Chief Scientific Officer of Oncology | — | male |
| Eric Michael David | Chief Executive Officer of Gene Therapy | — | — |
| Jonathan C. Fox FACC | President & Chief Medical Officer of Cardiovascular and Renal Diseases | — | — |
| Adora Ndu | Chief Regulatory Affairs Officer | — | — |
| Matthew Outten | Chief Commercial Officer | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Political Trading Activity (25M)
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
| Transaction Date | Disclosed | Representative | District | Owner | Type | Amount | Link |
|---|---|---|---|---|---|---|---|
| 2026-03-19 | 2026-04-08 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2026-03-18 | 2026-04-08 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2026-03-03 | 2026-04-08 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-09-22 | 2025-10-10 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
| 2025-08-08 | 2025-09-12 | Gilbert Cisneros | CA31 | — | Purchase | $1,001 - $15,000 | ↗ |
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BBIO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
